Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure.
about
A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzymePirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failurePretreatment with ACE inhibitors improves acute outcome of electrical cardioversion in patients with persistent atrial fibrillationAtrial fibrillation in heart failure: what should we do?Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes.The role of extracellular signal-related kinase during abdominal aortic aneurysm formationA role for CETP TaqIB polymorphism in determining susceptibility to atrial fibrillation: a nested case control studyAtrial Fibrillation Complicating Congestive Heart Failure: Electrophysiological Aspects And Its Deleterious Effect On Cardiac Resynchronization TherapyImpact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodelingAngiotensin-converting enzyme inhibitors and angiotensin receptor blockers decrease the incidence of atrial fibrillation: a meta-analysis.Recent advances in pharmacotherapy of atrial fibrillationPromoter polymorphism G-6A, which modulates angiotensinogen gene expression, is associated with non-familial sick sinus syndromeLeft atrial function predicts heart failure hospitalization in subjects with preserved ejection fraction and coronary heart disease: longitudinal data from the Heart and Soul StudyNew insights into the mechanisms and management of atrial fibrillationMkk4 is a negative regulator of the transforming growth factor beta 1 signaling associated with atrial remodeling and arrhythmogenesis with age.Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation.Atrial fibrosis and the mechanisms of atrial fibrillationEarly and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'.Molecular basis of selective atrial fibrosis due to overexpression of transforming growth factor-β1.Evidence for enhanced M3 muscarinic receptor function and sensitivity to atrial arrhythmia in the RGS2-deficient mouse.TheTGFB1 functional polymorphism rs1800469 and susceptibility to atrial fibrillation in two Chinese Han populations.Association of left atrial fibrosis detected by delayed-enhancement magnetic resonance imaging and the risk of stroke in patients with atrial fibrillationSR calcium handling dysfunction, stress-response signaling pathways, and atrial fibrillation.Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study.Atrial electrophysiology and mechanisms of atrial fibrillation.NF-kappaB-dependent transcriptional regulation of the cardiac scn5a sodium channel by angiotensin II.AdipoR1/APPL1 potentiates the protective effects of globular adiponectin on angiotensin II-induced cardiac hypertrophy and fibrosis in neonatal rat atrial myocytes and fibroblastsEffects of candesartan, an angiotensin II receptor type I blocker, on atrial remodeling in spontaneously hypertensive rats.Atrial fibrillation after radiofrequency ablation of atrial flutter: preventive effect of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and diuretics.Current perspectives of electrical remodeling and its therapeutic implications.Polymorphism modulates symptomatic response to antiarrhythmic drug therapy in patients with lone atrial fibrillation.Association between Postoperatively Developed Atrial Fibrillation and Long-Term Mortality after Esophagectomy in Esophageal Cancer Patients: An Observational StudyFibrosis in Atrial Fibrillation - Role of Reactive Species and MPO.New antiarrhythmic agents for atrial fibrillation and atrial flutter.How Are n-3 LCPUFAs Antiarrhythmic? A Reassessment of n-3 LCPUFAs in Cardiac Disease.Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1.Drug therapy for atrial fibrillation: where do we go from here?Is atrial fibrillation an inflammatory disorder?Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence.Drug Insight: angiotensin-converting-enzyme inhibitors and atrial fibrillation--indications and contraindications.
P2860
Q24306614-A6C651A8-3519-4913-A500-8C50E24853ACQ24684669-8B6FBDA2-49AB-489E-8A76-F19144DFB700Q24801156-23895622-B53D-4B71-89EE-592D945DF305Q26784426-B0A04D6D-4B58-4D1B-B06B-4174E386010EQ30234626-C65B4012-6837-4AB2-B3B4-9C025F7D497BQ30416591-D20F5220-C7F8-4F72-A230-11F4AA76571DQ33240337-C7013B57-8174-4002-9155-710F50ABBAF7Q33585671-E4EA78B3-EB5F-44DA-9985-0134708F52A5Q33775560-D89EAE3F-CA0B-4784-9F1E-A8939C8F68EAQ33798432-255FED9E-14BF-49D6-B011-2E8646F71F0DQ33874035-FACC3644-41C1-4DF4-B9CF-FCA11D53BE65Q34126711-6709A92A-93DB-4EB4-8904-0A49F8622657Q34155579-93086F48-E2F7-4F57-B143-68B390B585AEQ34289414-05A606EC-24E0-4504-AFC5-D88F2CA73CBDQ34297226-625587F2-5B71-4CBF-89BE-2894CC5002EFQ34575287-DEABE4A8-6859-4C22-A2D8-91E49DA4C82EQ34576855-91D896B3-70CE-4CFB-8E70-F4335127A6A5Q34609020-28807179-39E7-4319-923D-DCE27997CC52Q34650822-E66C1FAA-BE4E-4327-9A09-9ABC4F4300D8Q35016294-162EA03A-3DD7-4E2D-AB17-2056E910BD1EQ35070728-D8C76F8B-B003-427E-8887-339AD39C6CB8Q35071894-A966DA17-E14A-4250-9E2E-2E4120A2E586Q35099320-571740EC-B040-40EE-8698-F4E49502F5E1Q35116672-FE61DB4D-1904-4583-BD1D-A344E29D54C4Q35127387-D3FD6520-395C-4108-BCCE-AC6F222FB7B2Q35149277-92F59074-2450-40AC-83FA-DCFB917045BEQ35220392-A84E0E87-9F0C-431C-8A7D-A130FDE67BCDQ35294169-2633DFC4-12DF-49A3-AA2C-96A10D785B04Q35582807-610ECF33-6B50-4229-B2FC-369C293AF27CQ35862167-CDAD5F51-8B53-4435-9CFA-00871FF405A9Q35941124-B3319CAC-653B-4BDA-9AD3-36AFF78A3F53Q36009315-A6EB6CFC-BF1D-464D-85CF-0AB9B9470911Q36047754-C6C112F6-FD2D-4D7C-A2E1-7DB4EDCBAE55Q36150617-ABF43310-E203-4BAB-B89C-0954F4F254FCQ36199969-A9E6D642-0800-41ED-B699-A4F01091D2EAQ36249250-A353A34D-1C7D-4D38-9286-98919B5A153EQ36303805-27CE2AB0-9762-4EEE-8364-BBA65C622E47Q36309624-9B85C0B7-DAD0-475D-9251-074B091773C0Q36324110-587C9A9B-2BAB-4565-A905-B4920CE35A3AQ36433583-12506215-8F98-4A8A-BA93-BE46D46BA8D5
P2860
Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Effects of angiotensin-convert ...... uced congestive heart failure.
@en
Effects of angiotensin-convert ...... uced congestive heart failure.
@nl
type
label
Effects of angiotensin-convert ...... uced congestive heart failure.
@en
Effects of angiotensin-convert ...... uced congestive heart failure.
@nl
prefLabel
Effects of angiotensin-convert ...... uced congestive heart failure.
@en
Effects of angiotensin-convert ...... uced congestive heart failure.
@nl
P2093
P356
P1433
P1476
Effects of angiotensin-convert ...... uced congestive heart failure.
@en
P2093
K Shinagawa
P304
P356
10.1161/HC4601.099402
P407
P577
2001-11-01T00:00:00Z